Dr Sajeev Nair, Founder and Chairman, Vieroots
“The 2026–27 Union Budget presents an encouraging step in addressing the pressing need for affordable treatment of chronic illnesses such as diabetes and cancer. With initiatives like BioPharma Shakti, it becomes evident that biologic medicines are no longer niche therapies but are central to longevity, quality of life, and preventive healthcare at scale. By making an investment in biopharma manufacturing and strengthening regulatory institutions like the CDSCO with deeper scientific expertise and faster approval pathways, India is well positioned to make its mark as a global hub for high-quality, affordable biologics benefiting patients domestically and healthcare systems globally. These measures will definitely pave the way for a healthier, more informed society and will also align well with the broader shift toward personalised, preventive healthcare to boost longevity and quality of life. Alongside this, the budget also focuses on developing medical value tourism through regional healthcare hubs further giving an impetus to the sector’s growth. Affordable, high-quality care backed by strong regulation and advanced therapeutics enhances India’s global healthcare competitiveness while also upgrading domestic infrastructure. Together, these measures support a broader shift toward personalised, preventive healthcare that improves healthspan and quality of life. As a company working at the intersection of personalised wellness and nutrition, Vieroots sees strong alignment with this vision of preventive, longevity-focused healthcare and looks forward to contributing meaningfully to it.”
